Further to their role in the restriction of the immune response in viral infection and transplantation, there is evidence to suggest that the products of the major histocompatibility complex (MHC) genes may influence tumour growth and metastasis. This relationship has been extensively studied in vitro and in vivo using animal models (Goodenow et al., 1985) , and may also contribute to the behaviour of certain human tumours (Fleming et al., 1981; Ruiter et al., 1986; Doyle et al., 1985; Whelan et al., 1985; van den Ingh et al., 1987) . The mechanism(s) by which the MHC antigens modify tumour behaviour still require clarification (Demant, 1986; Festenstein, 1987) .
The class I antigens (HLA-A, -B, -C) are 45kD transmembrane glycoproteins noncovalently associated with a 12 kD invariant light chain, fl,2-microglobulin (f2m) (Strachan, 1987) . Their distribution is more restricted than was originally held (Daar et al., 1984) . The situation pertaining to hepatocytes is uncertain with some workers failing to detect them on normal liver cells (Ponder et al., 1983; Lautenschlager et al., 1984; Fukusato et al., 1986 ) and others reporting their presence at low levels (Saunders et al., 1979; Montano et al., 1982; Nagafuchi et al., 1985; Nagafuchi & Scheuer, 1986) .
Class II antigens (HLA-DP, -DQ, -DR) comprise two noncovalently linked transmembrane polypeptides (Lafuse & David, 1984) , associated for part of the cell cycle with another transmembranous glycoprotein, the invariant (I) chain (Jones et al., 1978) . Although their distribution is more widespread than originally recognised, it is generally agreed that hepatocytes do not express class II antigens in normal liver (Fukusato et al., 1986) . Both class I and class II products may be displayed by hepatocytes under a variety of pathological conditions, however (Nagafuchi et al., 1985; Fukusato et al., 1986; Nagafuchi & Scheuer, 1986; van den Oord et al., 1986) .
To date there is limited information available on HLA expression in hepatocellular carcinoma (HCC) with relatively few examples having been examined, either as solid tumours or cell lines (Natali 1981; Fukusato et al., 1986; Mazzeo et al., 1986) . We have therefore studied the pattern of expression of HLA-A, -B, -C and ,B2m, as well as HLA-DQ, HLA-DR and the associated I chain, using appropriate monoclonal and polyclonal antibodies. Monoclonal antibodies were demonstrated by a three step immunoperoxidase technique. Serial sections were rehydrated in PBS (pH 7.2) and incubated with the Mabs for 30 min at the dilutions specified above. The second and third steps comprised treatment for 30 min with rabbit-antimouse immunoglobulins (Igs) (Dako) at a dilution of 1:50, followed by peroxidase conjugated swine-antirabbit Igs (Dako), dilution 1:100, also for 30 min. Ten percent human AB serum was added to each, to reduce background staining. Each step was followed by vigorous washing in PBS. Sections were then incubated with 0.05% 3-amino-9-ethylcarbazole in 0.05M acetate buffer (pH4.9) and 0.01% H202. All staining was carried out at room temperature.
Polyclonal antibodies were used in a three-step unlabelled peroxidase-antiperoxidase procedure performed at room temperature. Sections were incubated with primary antibodies for 30min at the dilutions specified above, This was followed by swine-anti rabbit Igs (dilution 1:100) and, thereafter, rabbit peroxidase-antiperoxidase complex (Dako; dilution 1:300), both for 30 min. Sections were washed in three changes of PBS between steps. The reaction product was developed with 3-amino-9-ethylcarbazole and H202' Negative controls consisted of omission of the primary antibody or use of the chromogen alone.
Slides were examined in batches according to primary antibody to allow later comparison between MHC products and their relevant invariant chains. Staining of HLA-A, -B, -C and f2m was recorded as absent, cytoplasmic and membranous (± cytoplasmic). HLA-DR, -DQ and I chain staining were scored as 0 (absent), 1 + (<10% of hepatocytes positively staining), 2+ (10-50% positive), 3+ (>50% positive) and 4 + (>90% of cells positive). antigens, staining was considerably more intense than was observed in the control group. f2m staining accompanied HLA-A, -B, -C in all but two cases which were f22m negative but showed faint cytoplasmic HLA-A, -B, -C positivity. The pattern of expression was either cytoplasmic or membranous and generally correlated with the heavy chain.
Results
Class II expression Twenty-nine cases (41.4%) were positive for HLA-DR. Staining was invariably heterogeneous ( Figure 5 ). In 10 of these the extent of staining was graded as 1 +, 9 were read as 2+, 6 as 3 +, and 4 showed 4+ positivity.
All cases positive for HLA-DR also showed VICYI staining. In addition a further 4 cases were VICYI +/HLA-DR-. In contrast to the relationship between HLA-A, -B, -C and fl2m, however, I chain staining was invariably far in excess of that observed for its associated MHC product ( Figure 6 ). Thus, of 33 cases (47.1%) staining with VICY1, 4
were graded as 1+, 5 as 2+, 10 as 3+, and 14 showed 4+ positivity. For both Mabs, staining tended to be heterogenous, with (Immunoperoxidase x 400).
staining intensity varying from cell to cell. In tumours showing a pseudoglandular pattern the HLA-DR positivity was often confined to the apical portion of the cell ( Figure  5 ). Both antigens tended to be intracytoplasmic although in two tumours occasional small foci of membranous HLA-DR expression were noted. 
Discussion
In this study we have examined the patterns of MHC class I and II display in hepatocellular carcinoma. We have also attempted to qualify the relationship between these antigens and their respective invariant chains.
Expression of class I antigens by normal hepatocytes remains controversial. In our series of non-tumorous biopsies there was faint membranous expression of class I antigens by some liver cells. However such expression may represent a facile response of the hepatocyte to a variety of stimuli (Nagafuchi et al., 1985; Fukusato et al., 1986) . Biopsies read as histologically normal in this and other studies, and which express HLA-A, -B, -C, may not represent 'normal' liver, with unrecognised immunological factors or agents such as drugs or alcohol promoting the expression of HLA products at the hepatocyte membrane. This may explain the variable findings in the different series reported to date (Saunders et al., 1979; Montano et al., 1982; Ponder et al., 1983; Lautenschlager et al., 1984; Nagafuchi et al., 1985; Fukusato et al., 1986; Nagafuchi & Scheuer, 1986 (Fukusato et al., 1986; Mazzeo et al., 1986) .
This contrasts with the situation reported for other human tumours, including colorectal carcinomas in which there is sometimes loss of expression in comparison with the nonneoplastic epithelium (Daar et al., 1982; Csiba et al., 1984; Momburg et al., 1986; van den Ingh et al., 1987) . Furthermore it is suggested by some investigators that loss of display is related to progressive de-differentiation and prognosis van den Ingh et al., 1987) . This observation has also been made for malignant melanomas in which attenuated or absent class I expression is associated with a high degree of malignancy (Ruiter et al., 1986 ). We have not observed any relationship between MHC expression and tumour differentiation in HCC.
Class II antigens were expressed in nearly half of the cases in our series. Expression was heterogeneous and often rather sparce, however, and was always associated with VICY 1 positivity, although the latter typically showed far more extensive and intense staining than HLA-DR. The Mab VICYI is directed at the core protein of the class II-associated I chain proteoglycan (Giacoletto et al., 1986) . It is an unusual transmembranous glycoprotein with some structural similarity to certain membrane receptor molecules including the transferrin receptor (Creswell et al., 1987) . Its function at this time is unknown although it may participate in one or more of a variety of activities: biosynthesis, transport/recycling, immune mediation or other as yet unrecognised functions (Koch & Harris, 1984; Long, 1985; Giacoletto et al., 1986; Creswell et al., 1987) . Although some cases in our series expressed the I chain in the absence of HLA-DR, it may be that this represents tissue selection rather than true absence of HLA-DR, as the class II antigen is expressed extremely sparcely in some cases showing strong VICYI staining. It is noted, however, that the murine equivalent of the I chain has been demonstrated in the absence of class II antigen in B-lymphoid and myeloid cell lines (Koch & Harris, 1984) , and a subset of tumour cells in one case of mediastinal B-cell lymphoma has been reported to be positive for I chain in the absence of HLA-DR and -DQ (M6ller et al., 1986) . Furthermore, hyperexpression of the I chain has been demonstrated by electrophoretic techniques in Epstein-Barr virus-transformed leukaemic cells (Spiro et al., 1985) . To our knowledge the VICYI antibody has not previously been applied to epithelial neoplasms, and our observations suggest that it may be of value in the study of class II expression in other tumours. Although HLA-DR expression has been observed in reactive hepatocytes during HBV infection (Fachetti et al., 1985; van den Oord et al., 1986) , data for HLA-DQ expression are not available. We believe that the expression of HLA-DQ in some tumours in this series implies that nonneoplastic liver cells may also express this antigen, but in a sequential or dissociated fashion (Sollid et al., 1987) .
It has been suggested that the ability to display class II antigens in response to appropriate stimuli may be constitutive to all cells and that it is the failure to express the antigen by a percentage of tumours which represents the 'aberrant' state (Moore & Ghosh, 1987 The MHC antigens function primarily at the cell surface. In a significant minority of malignant hepatocytes expressing HLA-A, -B, -C, and in the vast majority displaying HLA-DR, expression is confined to the cytoplasm. This has also been observed with respect to class I antigens in other tumour systems (Lampert et al., 1985; Kadin, 1980 (Goodenow et al., 1985) . There is enhancement of metastatic potential in tumours showing loss or attenuation of class I antigens (Schrier et al., 1983) , this being reversible by transfection with the appropriate class I gene (Tanaka et al., 1985) . Furthermore, modified class I antigens may themselves act as tumour-specific antigens (Philipps et al., 1986) , or influence tumour behaviour by interaction with non-MHC genes or by an hormonal effect (Demant, 1986 (Ruiter et al., 1986) , breast carcinomas (Fleming et al., 1981) , small cell carcinoma of lung (Doyle et al., 1985) , and neuroblastomas (Whelan et al., 1985) . The possibility that this relationship may influence the behaviour of HCC merits some consideration.
HCC is a tumour associated with a uniformly fatal outcome unless detected and resected at an early stage (Kew & Geddes, 1984; Okuda, 1986) . Although progress from the time of diagnosis to death is typically rapid (Kew & Geddes, 1984) , there is a prolonged subclinical period (Sheu et al., 1985) and the tumour shows an early and sustained proclivity for capsular and blood vessel infiltration (Wakasa et al., 1985; Kew & Paterson, 1985) .
Advanced HCCs are typically massive and show extensive vascular infiltration and intrahepatic spread. Despite this, metastases are often confined to clinically insignificant hilar lymph node and pulmonary deposits (Anthony, 1978; Kew & Paterson, 1985) 
